Drugs / B7H3 Affibody-BCH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06454955 | Jan → Nov 2024 overdue | — | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7H3 Affibody-BCH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06454955 ↗ |
| Modality | Diagnostic / imaging agent | “suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3” NCT06454955 ↗ |